Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article

Sourouni, Marina; Kiesel, L.

doi:10.1055/a-1390-4353

Cited by 10 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed that MSH2 is not closely related to BMI, although obesity is a main risk factor for endometrial cancer (Kliemann et al, 2021;Sourouni & Kiesel, 2021). Age is another risk factor for endometrial cancer, and MSH2 expression is related to age (Chatsirisupachai et al, 2021;Deshpande et al, 2020).…”

Section: Discussionmentioning

confidence: 71%

High MutS homolog 2 expression predicts poor prognosis and is related to immune infiltration in endometrial carcinoma

Ying

Zhang

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

Several studies have shown that MutS homolog 2 (MSH2) is highly expressed in many cancer tissues. Transcriptome expression data were collected from the Cancer Genome Atlas (TCGA) database. We analyzed the expression of MSH2 in normal and tumor tissues, the relationship between MSH2 expression and various prognostic factors, and the relationship between MSH2 expression and overall survival, disease specific survival, and progression free interval. We also examined MSH2 promoter methylation between endometrial cancer and normal endometrial tissues, and identified the prognostic value of MSH2 methylation in endometrial cancer. MSH2 was highly expressed in endometrial cancer tumor tissues compared with normal tissues. High MSH2 expression might be an independent prognostic factor for OS, DSS, and PFI. Further, high MSH2 expression was correlated with age and histological type, but not with BMI, clinical stage, tumor invasion, or other clinical features. MSH2 promoter methylation in endometrial cancer was significantly lower than in normal tissues. Additionally, MSH2 levels, OS, DSS, and PFI were associated with BMI, age, tumor invasion, and histological type. ssGSEA showed that MSH2 expression was positively correlated with the infiltration of Th2 cells, Tcm cells, T helper cells, and Tgd cells, whereas it was negatively correlated with NK CD56 bright cells, pDC cells, iDC cells, cytotoxic cells, and neutrophils. Increased MSH2 expression and reduced MSH2 methylation in endometrial cancer predicts poor prognosis. MSH2 may be used as a biomarker for the diagnosis and prognosis of endometrial cancer and as an immunotherapy target.

show abstract

Section: Discussionmentioning

confidence: 71%

High MutS homolog 2 expression predicts poor prognosis and is related to immune infiltration in endometrial carcinoma

Ying

Zhang

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…Continuous endometrial exposure to oestrogens increases the risk of endometrial hyperplasia and cancer, but adding progestogen has a protective role. However, there is a lack of research on HT regarding endometrial cancer [36]. Furthermore, no consensus has been achieved on the best progestogen, dosage, administration method, therapy duration, and the follow-up protocol [37].…”

Section: Endometrial Cancermentioning

confidence: 99%

Applications of Photodynamic Therapy in Endometrial Diseases

et al. 2022

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a medical procedure useful for several benign conditions (such as wound healing and infections) and cancer. PDT is minimally invasive, presents few side effects, good scaring, and is able to minimal tissue destruction maintaining organ anatomy and function. Endoscopic access to the uterus puts PDT in the spotlight for endometrial disease treatment. This work systematically reviews the current evidence of PDT’s potential and usefulness in endometrial diseases. Thus, this narrative review focused on PDT applications for endometrial disease, including reports regarding in vitro, ex vivo, animal, and clinical studies. Cell lines and primary samples were used as in vitro models of cancer, adenomyosis and endometrioses, while most animal studies focused the PDT outcomes on endometrial ablation. A few clinical attempts are known using PDT for endometrial ablation and cancer lesions. This review emphasises PDT as a promising field of research. This therapeutic approach has the potential to become an effective conservative treatment method for endometrial benign and malignant lesions. Further investigations with improved photosensitisers are highly expected.

show abstract

“…Patients suffering from breast cancer who develop menopausal symptoms pose a major challenge as HRT may increase the risk of recurrence. The data for this are insufficient to derive a standardized procedure [6]. Individual advice is of particular importance in this case.…”

Section: Introductionmentioning

confidence: 99%

Menopausal Hormone Therapy and the Breast: A Review of Clinical Studies

Sourouni

Kiesel

2023

Breast Care

View full text Add to dashboard Cite

Background: Women in the peri- or postmenopause can experience symptoms related to the gradual degradation of ovarian function. Hormone replacement therapy (HRT) is the most effective therapy to treat common menopausal symptoms such as hot flashes and vaginal discomfort. However, safety concerns have been raised revolving among others also around the risk of breast cancer. Methods: This article is based on a selective literature search for relevant studies regarding HRT use and the risk of breast cancer in general population or BRCA carriers, risk of breast cancer recurrence or risk for breast cancer in situ (BCIS). Summary: HRT can lead to little or no increase in breast cancer risk. The risk depends on the duration and composition of the HRT and decreases after stopping the treatment. Data assessing the oncological safety of HRT after breast cancer is inconsistent. According to current knowledge HRT is fundamentally contraindicated after breast cancer but can be individually considered after risk-benefit assessment and when non hormonal therapies have failed. The same applies to a HRT after DCIS, which should not be routinely offered but nonetheless can be considered in individual cases. HRT can be offered up to the age of natural menopause for BRCA mutation carriers who are undergoing risk-reducing bilateral salpingo-oophorectomy (RRSO) and do not have a personal history of breast cancer but is contraindicated in BRCA mutation carriers who have already had breast cancer.

show abstract

Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article

Cited by 10 publications

References 32 publications

High MutS homolog 2 expression predicts poor prognosis and is related to immune infiltration in endometrial carcinoma

High MutS homolog 2 expression predicts poor prognosis and is related to immune infiltration in endometrial carcinoma

Applications of Photodynamic Therapy in Endometrial Diseases

Menopausal Hormone Therapy and the Breast: A Review of Clinical Studies

Contact Info

Product

Resources

About